GGrantIndex
← Search

Biostatistics Shared Resource

$159,145P30FY2024CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

Program Director/Principal Investigator (Last, First, Middle): Chu, Edward BIOSTATISTICS SHARED RESOURCE - PROJECT SUMMARY/ABSTRACT The increasing variety and complexity of data types, analytic approaches and study designs utilized in cancer research necessitate the availability of an organized and centralized biostatistics resource that can offer a wide range of statistical expertise, collaboration, and training opportunities to investigators at the Montefiore Einstein Cancer Center (MECC). The Biostatistics Shared Resource (BSR) is staffed by experienced statisticians with strong track records in effective collaboration across all scientific programs, innovative research in cancer relevant statistical areas, and in training and mentoring investigators at all levels. BSR personnel have critical roles in enhancing the Center infrastructure and fostering multi-disciplinary team science given their broad knowledge of the scope of research activities within the MECC and active involvement on various cancer center committees. The specific objectives of the BSR are: (i) To provide state-of-the-art biostatistical and bioinformatic support on all phases of cancer research, from experimental design and study conduct to data analysis and manuscript preparation; (ii) To collaborate on the development of methodologically rigorous grant applications and new research initiatives; (iii) To assist with the development and scientific review of clinical trial protocols; (iv) To develop innovative biostatistics and bioinformatics approaches to address analytical challenges from new technologies in cancer research; (v) To offer a wide range of biostatistics training opportunities to MECC members and to mentor junior cancer investigators; (vi) To enhance the MECC infrastructure and foster interdisciplinary collaborations via participation on scientific and administrative committees and interactions with other shared resources. In the next funding period, to be in line with the strategic research priorities of the MECC, the BSR will focus on strengthening methodological expertise to address the anticipated needs of existing and newly recruited MECC researchers. Specifically, we have recently established the Subcore of Clinical Trials Methodology focusing on novel clinical trials and pragmatic trials on cancer screening and therapy. In addition, we aim to increase expertise in machine learning approaches that can integrate clinical, laboratory, and different types of high dimensional omics data on cancer etiology, prognosis and precision medicine and prevention and to increase research to address health disparities. The overall goal in accomplishing these objectives is to provide a robust, comprehensive and cost-effective system of statistical support for MECC investigators that contributes significantly to advancing the understanding of cancer etiologies and prognosis, as well as improving cancer prevention, detection and treatment strategies. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page

View original record on NIH RePORTER →